These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 29462502)

  • 21. The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies.
    Conrad MA; Kelsen JR
    Curr Gastroenterol Rep; 2020 Jun; 22(8):36. PubMed ID: 32542562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring.
    Albader F; Golovics PA; Gonczi L; Bessissow T; Afif W; Lakatos PL
    World J Gastroenterol; 2021 Oct; 27(37):6231-6247. PubMed ID: 34712029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease.
    Hemperly A; Sandborn WJ; Vande Casteele N
    Inflamm Bowel Dis; 2018 Nov; 24(12):2527-2542. PubMed ID: 29788338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Infliximab pharmacokinetics monitoring in inflammatory bowel disease].
    Svoboda P; Kupka T
    Vnitr Lek; 2020; 66(8):34-38. PubMed ID: 33740858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-Tumor Necrosis Factor Alpha Therapeutic Drug Monitoring in Inflammatory Disease: A Systematic Review.
    Schneider C; Stratman S; Choragudi S; Lev-Tov H
    J Drugs Dermatol; 2023 May; 22(5):445-450. PubMed ID: 37133467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New Zealand Society of Gastroenterology Guidelines on Therapeutic Drug Monitoring in Inflammatory Bowel Disease.
    Khan A; Berahmana AB; Day AS; Barclay ML; Schultz M
    N Z Med J; 2019 Mar; 132(1491):46-62. PubMed ID: 30845128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease.
    Cheifetz AS; Abreu MT; Afif W; Cross RK; Dubinsky MC; Loftus EV; Osterman MT; Saroufim A; Siegel CA; Yarur AJ; Melmed GY; Papamichael K
    Am J Gastroenterol; 2021 Oct; 116(10):2014-2025. PubMed ID: 34388143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives.
    Papamichael K; Afif W; Drobne D; Dubinsky MC; Ferrante M; Irving PM; Kamperidis N; Kobayashi T; Kotze PG; Lambert J; Noor NM; Roblin X; Roda G; Vande Casteele N; Yarur AJ; Arebi N; Danese S; Paul S; Sandborn WJ; Vermeire S; Cheifetz AS; Peyrin-Biroulet L;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):171-185. PubMed ID: 35026171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic Drug Monitoring of Biologics in Crohn's Disease.
    Grossberg LB; Cheifetz AS; Papamichael K
    Gastroenterol Clin North Am; 2022 Jun; 51(2):299-317. PubMed ID: 35595416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments.
    Lee SD; Shivashankar R; Quirk D; Zhang H; Telliez JB; Andrews J; Marren A; Mukherjee A; Loftus EV
    J Clin Gastroenterol; 2021 Mar; 55(3):195-206. PubMed ID: 32740098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward?
    Strik AS; Berends SE; Löwenberg M
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):885-891. PubMed ID: 31305158
    [No Abstract]   [Full Text] [Related]  

  • 32. Personalized Dosing of Infliximab in Patients With Inflammatory Bowel Disease Using a Bayesian Approach: A Next Step in Therapeutic Drug Monitoring.
    Desai DC; Dherai AJ; Strik A; Mould DR
    J Clin Pharmacol; 2023 Apr; 63(4):480-489. PubMed ID: 36458468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advantages of Proactive Therapeutic Drug Monitoring in a Prospective Cohort of Children With Inflammatory Bowel Disease Treated With Anti-Tumour Necrosis Factor.
    Gasparetto M; Burgess N; Naik S; Studart D; Kadir A; Croft N; Sanderson I; Deb P
    J Pediatr Gastroenterol Nutr; 2022 Apr; 74(4):484-489. PubMed ID: 35129158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.
    Mitrev N; Vande Casteele N; Seow CH; Andrews JM; Connor SJ; Moore GT; Barclay M; Begun J; Bryant R; Chan W; Corte C; Ghaly S; Lemberg DA; Kariyawasam V; Lewindon P; Martin J; Mountifield R; Radford-Smith G; Slobodian P; Sparrow M; Toong C; van Langenberg D; Ward MG; Leong RW;
    Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1037-1053. PubMed ID: 29027257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Outcomes With Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis.
    Ricciuto A; Dhaliwal J; Walters TD; Griffiths AM; Church PC
    J Crohns Colitis; 2018 Nov; 12(11):1302-1315. PubMed ID: 30107416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.
    Khanna R; Sattin BD; Afif W; Benchimol EI; Bernard EJ; Bitton A; Bressler B; Fedorak RN; Ghosh S; Greenberg GR; Marshall JK; Panaccione R; Seidman EG; Silverberg MS; Steinhart AH; Sy R; Van Assche G; Walters TD; Sandborn WJ; Feagan BG
    Aliment Pharmacol Ther; 2013 Sep; 38(5):447-59. PubMed ID: 23848220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Evolving Evidence for Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory Bowel Disease.
    Sheasgreen C; Nguyen GC
    Curr Gastroenterol Rep; 2017 May; 19(5):19. PubMed ID: 28397129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
    Nguyen NH; Solitano V; Vuyyuru SK; MacDonald JK; Syversen SW; Jørgensen KK; Crowley E; Ma C; Jairath V; Singh S
    Gastroenterology; 2022 Oct; 163(4):937-949.e2. PubMed ID: 35753383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease.
    Mitrev N; Leong RW
    Expert Opin Drug Saf; 2017 Mar; 16(3):303-317. PubMed ID: 27922765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.
    Alsoud D; Moes DJAR; Wang Z; Soenen R; Layegh Z; Barclay M; Mizuno T; Minichmayr IK; Keizer RJ; Wicha SG; Wolbink G; Lambert J; Vermeire S; de Vries A; Papamichael K; Padullés-Zamora N; Dreesen E
    Ther Drug Monit; 2024 Jun; 46(3):291-308. PubMed ID: 38648666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.